-dependent growth arrest without apoptosis.
Introduction
The mitogen-activated protein kinase (MAPK) superfamily is currently comprised of three pathways, including classical MAPK, also called ERK, stress activated protein kinases, known as JNK, and osmotic shock-regulated kinase, or p38. 1 The classical MAPK module consists of three sequentially acting protein kinases, Raf-1, MEK and ERK (extracellular ligand regulated kinases). Raf-1 kinase has a central role in regulating proliferation, differentiation and apoptosis. Raf-1 is downstream of Ras, and tyrosine kinases, such as Lck, Src, Abl; and activated Raf oncoprotein can abrogate cytokine dependency in hematopoietic cells. 2 Also, protein kinase C (PKC) activates Raf-1 by direct phosphorylation, 3 which requires formation of Ras-Raf complexes. 4 The activation of Raf-1 and mitogen-activated pathways may explain a partial capacity of phorbol ester (TPA), a PKC activator, to substitute for growth factors in quiescent cells. 5 In contrast, proliferating leukemia cells may undergo differentiation and growth inhibition by phorbol ester, 6, 7 an observation whose clinical application was recently studied. 8 Raf-1 phosphorylation and activation are required for cytostatic and differentiating activity of TPA in leukemia cells. 9 Microtubule-active drugs including paclitaxel (PTX), vincristine and vinblastine also cause hyperphosphorylation and activation of Raf-1 kinase. 10, 11 Similarly, Raf-1 hyperphosphorylation and activation was demonstrated during nocodazole- induced and normal mitotic arrest. [12] [13] [14] [15] Like Raf-1, Bcl-2 protein is phosphorylated following exposure to microtubuleactive drugs, and this has been speculated to be a mechanism for eliminating cells with severe chromosomal disruption. 10, 16 Members of the Bcl-2 family can substitute for each other, 17 and cells with low Bcl-2 levels express high BclxL, and BclxL is also phosphorylated by microtubule-active drugs. 18 Although the growth inhibition of leukemia cells by TPA was described more than 20 years ago, 6, 7 the agent was only recently studied for treatment of leukemia. 8 Like microtubuleactive drugs, TPA activates Raf-1 and p38 kinases, [19] [20] [21] implying common steps in anti-leukemia activity of TPA and microtubule-active drugs. Here we show that Raf-1-associated Bcl-2 phosphorylation and apoptosis following treatment with microtubule-active drugs does not involve the MAPK pathway, whereas growth arrest by phorbol ester depends on the MAPK cascade and p21 WAF1/CIP1 induction. In contrast to microtubule-active drugs, phorbol ester induces neither Bcl-2 phosphorylation nor its cleavage in leukemia cells.
Materials and methods

Cell lines
Human myeloid leukemia cells, HL60 and U937; human T cell leukemia cells, Jurkat, and an Lck-deficient clone of Jurkat cells, J.CAM1.6, were obtained from ATCC and cultured in RPMI plus 10% FBS. UP293 cells were obtained from Dr P Seth (NCI, NIH) and cultured in RPMI plus 10% FBS.
Reagents
Phorbol 12-myristate 13-acetate (PMA/TPA, Sigma, St Louis, MO, USA), PD98059 and SB202190 (New England BioLabs, Beverly, MA, USA), and Geldanamycin (GA; Development Therapeutics Program, NCI, NIH) were dissolved in DMSO at concentrations of 1 mm, 20 mm, 20 mm and 10 mm respectively and stored at −20°C protected from light. Paclitaxel (Taxol) was a Bristol-Myers (Princeton, NJ, USA) product with a stock solution 6 mg/ml. Final concentrations of DMSO solvent varied but did not exceed 0.01% for 100 ng/ml of paclitaxel or TPA, and never exceeded 0.1% for other compounds, and DMSO did not exert any effects at these concentrations. Vincristine, vinblastine and nocodazole were prepared as previously described. 10 Forskolin, 8-Br-c-AMP, and sodium butyrate were prepared as 1 mm, 100 mm and 1 m stock solution in water, respectively.
Transient transfection assay
TRE-Luc, a TPA responsive element promoter-luciferase construct, was a gift of CM Zacharchuk (NCI, NIH) and it usage was described previously. 22 Activated H-ras-V12 cloned into the EcoRI site of the pEXV plasmid and a control vector were provided by Dr X-Y Zeng (University of Pennsylvania); MEKK1 23 was provided by Dr JS Gutkind (NIDR, NIH). Bcl-2 cloned in pSFFV neo plasmid 24 was provided by Dr Thompson (University of Chicago). 8 × 10 5 UP293 cells were plated into six-well plates. The next day, cells were transfected with plasmids using Lipofectamine (Gibco BRL, Rockville, MD, USA). After 12 h of incubation with the plasmid-lipid suspension, medium was changed and cells were incubated for an additional 24 h. The cells were then lysed and analyzed for luciferase activity as recommended by Promega, Madison, WI, USA.
Western blot analysis
Proteins were harvested in TNESVF buffer (50 mm Tris HCl (pH 7.5), 2 mm EDTA, 100 mm NaCl, 1 mm sodium ortovanadate, sodium fluoride, 1% NP-40) with protease inhibitors and were resolved on 12.5% SDS-PAGE for p21 WAF1/CIP1 , and pp44/42 (phospho ERK1/ERK2) analysis, or on 7.5% SDS-PAGE for Rb, poly(ADP-ribose) polymerase (PARP), Raf-1 and B-Raf detection as previously described. 25 Immunoblotting for p21 WAF1/CIP1 , Rb and Raf-1 was performed using the following antibodies: antihuman WAF1 monoclonal (EA10, Oncogene Science, Calbiochem, San Diego, CA, USA), anti-Rb monoclonal (Oncogene Science), anti-PARP rabbit polyclonal (Upstate Biotechnology, Lake Placid, NY, USA), anti-Raf-1 rabbit polyclonal (C12; Santa Cruz, Biotechnology, Santa Cruz, CA, USA), and anti-B-Raf rabbit polyclonal (Upstate Biotechnology), and anti-ERK-2 rabbit polyclonal (C14; Santa Cruz). The activation of MAP kinase was monitored with the highly specific anti-phospho (T183/Y185) ERK1 and ERK2 antibodies (New England BioLabs).
Immunoprecipitation
Proteins were harvested using TNESVF buffer and 200 g proteins were incubated with anti-Bcl2 antibodies rabbit polyclonal (N 19; Santa Cruz) for 2 h. Then 100 l of protein ASepharose CL-4B (PAS) beads (Pharmacia, Uppsala, Sweden) were added, and incubation continued for an additional 1 h. The beads were washed three times in TNESVF buffer and then resuspended in SDS loading buffer. 3 
H-thymidine incorporation and MTT assay
3 H-thymidine incorporation and MTT assay were performed as described. 25 In brief, 15 000 HL60 cells were plated in 96-well flat bottom plates (Costar, Corning, NY, USA) and cells were treated with the indicated drugs for 20 h ( 3 H-thymidine assay) or for 3 days (MTT assay). For 3 H-thymidine incorporation 1 Ci of 3 H-thymidine was added to each well for an additional 4 h; for MTT assay, 20 l of 5 mg/ml MTT solution in PBS was added to each well for 4 h.
Results
Bcl-2/Raf-1 phosphorylation is a hallmark of cytotoxicity of microtubule-active drugs in leukemia cells
Raf-1/Bcl-2 phosphorylation is associated with poly(ADPribose) polymerase (PARP) cleavage, a marker of caspase activation, and cytotoxicity in leukemia cells following paclitaxel exposure ( Figure 1 ). Doses of PTX above 10 ng/ml cause cell death and therefore further increase of concentration of PTX could not be more cytotoxic (Figure 1a ). The same pattern was observed with Raf-1 and Bcl-2 mobility shift ( Figure 1b) . As previously demonstrated, [11] [12] [13] [14] [15] the mobility shift of Raf-1 protein following treatment with microtubule-active drugs is associated with Raf-1 hyperphosphorylation on serine residues and also Raf-1 kinase activation. Similarly, the slower migrating bands of the Bcl-2 protein represent phosphorylation of Bcl-2 on serine. 18, [26] [27] [28] Caspase activation is the central event in apoptosis that is triggered in response to apoptotic signals and culminates in cleavage of a set of proteins, including PARP. 29 In agreement with previous reports that paclitaxel induces apoptosis in leukemia cells, 30, 31 we observed PARP cleavage following 16-20 h of paclitaxel exposure (Figure 1b ). Like paclitaxel, other microtubule-active drugs vinblastine and nocodazole induced Raf-1 and Bcl-2 phosphorylation which was accompanied by the PARP cleavage (data not shown). 
MAPK activation by TPA induces p21 WAF1/CIP1 and growth arrest
Phosphorylation of Raf-1 and ERK MAP kinases but not Bcl-2 phosphorylation was observed in HL60 cells after 20 min of treatment with TPA ( Figure 2a ). As expected, PD98059, a selective MEK inhibitor, abrogated phosphorylation of ERK MAPK. In agreement with a previous report, this abolished Raf-1 hyperphosphorylation by TPA. 32 The ERK MAPK activation by TPA was short lived and, as overexposed films revealed (Figure 2b ), ERK phosphorylation returned to the
Figure 2
Comparison of paclitaxel (PTX) and phorbol ester (TPA) signaling. HL60 cells were incubated with or without 100 ng/ml PTX or TPA as indicated. Where indicated, (+), cells were preincubated with 10 m of PD98059, a MEK inhibitor. CTRL, control, cells were incubated with in RPMI with 10% FBS. Concentrations of DMSO never exceeded 0.1% and exert no effect (data not shown). 
Paclitaxel-induced Bcl-2 phosphorylation and apoptosis is not mediated by MAPK
In contrast to TPA, short-term treatment with paclitaxel did not induce Raf-1 shift (Figure 1a ) which is consistent with delayed kinetics of the mitotic arrest. Paclitaxel induced Raf-1 phosphorylation at a later time point (Figure 2b ) but did not induce ERK MAPK phosphorylation on activation-specific Y/T residues and did not cause ERK mobility shift (Figure 2b ). Overexposed films which allow detection of basal levels of ERK MAPK activation demonstrate no difference between control and PTX-treated cells (Figure 2b) . Also, no phosphorylation was detected by labelling of ERK with 32 P-phosphate (data not shown). Therefore, not unexpectedly, paclitaxel-induced hyperphosphorylation of Bcl-2 was not affected by PD98059. This indicates that ERK MAPK pathway is dispensable for paclitaxel-induced apoptosis. Since paclitaxel-induced phosphorylation of Raf-1/Bcl-2 occurs by 6 h of treatment, we investigated Bcl-2 phosphorylation when PD98059 was added 6 h after paclitaxel to exclude the possibility of PD98059 degradation in culture, respectively. Delayed treatment with PD98059 also did not affect paclitaxel-induced Bcl-2 phosphorylation or cytotoxicity in HL-60 cells. Similarly, Raf-1/Bcl-2 phosphorylation and apoptosis were PD98059-insensitive in Jurkat, T cell leukemia cells (data not shown).
Consistent with requirement of MAPK activation for p21 WAF1/CIP1 induction, paclitaxel did not induce p21
in HL60 cells (Figure 2 ). In accordance, no Rb dephosphorylation was detected following paclitaxel treatment (Figure 2b ). Although paclitaxel induces p53 and p21 WAF1/CIP1 in some non-hematopoietic cancer cell lines, such as MCF-7 and A549; this induction is cell type specific; and p21 WAF1/CIP1 was not induced by paclitaxel in HL-60 (p53 null) or in Jurkat (p53 mutant) leukemia cells.
Overexposed Bcl-2 immunoblots revealed a 22 kDa Bcl-2 cleavage product following paclitaxel exposure (Figure 2b) . The appearance of the 22 kDa Bcl-2 product coincident with caspase activation as indicated by PARP cleavage (Figure 2b ). Both PARP and Bcl-2 cleavage were PD98059-insensitive (Figure 2b) . It has been recently demonstrated that activated caspase-3 cleaves Bcl-2 protein at Asp34, converting Bcl-2 from the anti-apoptotic to pro-apoptotic state. 33 To confirm that 22 kDa products lacks N-terminus, we immunoprecipitated Bcl-2 with polyclonal antibodies raised against 4-19 aminoacids (Figure 3 ). These N-terminus specific antibodies immunoprecipitated full-length Bcl-2 but not 22 kDa Bcl-2 product (Figure 3 ).
Paclitaxel, MEKK1 and H-Ras activate a TPA responsive element but only paclitaxel phosphorylates Bcl-2
To extend an observation that the MAPK pathway is not involved in Bcl-2 phosphorylation, we next employed transient transfection strategies using MEKK1 and H-ras expression vectors. MEKK1, a serine/threonine kinase, and H-ras activate Paclitaxel generates 22 kDa Bcl-2 product lacking N-terminus. HL60 cells were treated with paclitaxel for 18 h. Bcl-2 was determined by immunoblotting with monoclonal anti-Bcl-2 antibodies against 41-54 residues. Total, 20 g of total soluble cellular proteins were used for detection of Bcl-2 and 22 kDa product; i.p., 200 g of cellular protein was immunoprecipitated with rabbit polyclonal antibodies raised against 4-19 residues (N19; Santa Cruz). Monoclonal Bcl-2 antibodies against 41-54 residues (DAKO, Carpinteria, CA, USA) were used for immunoblotting.
both the JNK and the ERK MAPK pathways.
1 UP293 cells were chosen for these studies, because they express low endogenous levels of Bcl-2 and are characterized by high transfection efficiency. UP293 cells were transfected with Bcl-2-expressing plasmid with or without MEKK1 or H-Ras; Bcl-2 phosphorylation was determined by Western blot. In addition, to evaluate the effects of MEKK1 and H-ras on TPA responsive element (TRE), an endpoint of both the JNK and the ERK MAPK pathways, 34 a TRE-luciferase construct was co-transfected. While paclitaxel slightly activated TRE-Luc consistent with previous observation, 35 both MEKK1 and H-Ras markedly activated TRE-Luc (Figure 4a, b) . On the other hand, neither MEKK1 nor H-Ras caused Bcl-2 phosphorylation (Figure 4c ). These results indicate that paclitaxel, a weak activator of TRE-Luc, induces Bcl-2 hyperphosphorylation, whereas MEKK1 and H-Ras, potent activators of the JNK or ERK MAPK, do not induce Bcl-2 hyperphosphorylation.
Phosphorylation of Raf-1/Bcl-2 by paclitaxel in Lckdeficient cells
Previous data support the notion that Raf-1/Bcl-2 phosphorylation by microtubule-active drugs is not dependent on classical signaling pathways. One can predict that the absence of a key signaling molecule which connects the membrane-associated events with Raf-1 should not affect Raf-1/Bc-2 phosphorylation. Here we take advantage of a Lck-deficient clone of the T cell leukemia cell line, J.CAM1.6. 36 Lck is a tyrosine protein kinase, that is essential for T cell signaling from the plasma membrane to the Raf-1 kinase. 37, 38 Consistent with direct phosphorylation of Raf-1 by PKC, Raf-1 was phosphorylated following TPA exposure in both Jurkat and J.CAM1.6 cells ( Figure 5 ). Paclitaxel caused Raf-1 and Bcl-2 hyperphosphorylation in both cell lines, indicating this pathway is also Lck-independent. Pretreatment with the benzoquinone ansamycin, Geldanamycin (GA), which causes Raf-1 depletion 22 abrogated paclitaxel-mediated Bcl-2 phosphorylation in both cell lines. This observation is consistent with the notion that Raf-1 and Bcl-2 phosphorylation is tightly coupled although it does not prove that Raf-1 mediates Bcl-2 phosphorylation. Thus, depletion of Raf-1 by GA causes growth arrest, 39 and this may preclude mitotic arrest by paclitaxel. Although, the role of Raf-1 in Bcl-2 phosphorylation remains circumstantial, the two events are tightly associated, because both of them occurs during mitotic arrest. 12, 28, 40 Requirement of Lck for Raf-1 phosphorylation during mitotic arrest was previously investigated during nocodazoleinduced mitotic arrest. 41 Therefore, we next compared the effects of nocodazole and paclitaxel in Jurkat and J.CAM1.6 cells. Like paclitaxel, nocodazole induced Raf-1 phosphorylation (Figure 5b ). This is consistent with the notion that all microtubule active drugs induce Raf-1 phosphorylation. 10 Our data are in contrast to a report that Raf-1 phosphorylation was not observed in a nocodazole-treated J.CAM1.6. 41 However,
Figure 5
Effect of paclitaxel and TPA in parental Jurkat and Lckdeficient clone J.CAM1.6. (a) Jurkat or J.CAM1.6 cells were treated with 100 ng/ml TPA, 100 ng/ml paclitaxel (PTX) and 1 m Geldanamycin (GA) alone or in combination for 16 h. Raf-1, Bcl-2 and p21 immunoblot was performed as described in Methods. (b) Jurkat or J.CAM1.6 cells were treated with 100 ng/ml paclitaxel (PTX) or nocodazole (Noco). Immunoblot was performed after 16 h. PARP, Raf-1, and Bcl-2 proteins were measured by immunoblot.
as we noticed, Raf-1 protein levels were decreased in nocodazole-treated cells. 41 In underexposed films, the phosphorylated Raf-1 (lighter band in J.CAM1.6 cells, Figure 5b ) may become less visible. Therefore, the apparent decrease of Raf-1 protein that was observed by Pathan et al 41 may, in fact, represent Raf-1 phosphorylation. Failure to detect Raf-1 shift in Lck-deficient cells perhaps due to insufficient sensitivity prompted Pathan et al to conclude that Lck tyrosine kinase directly phosphorylates Raf-1 during mitotic arrest. 41 As discussed, this model could not be reconciled with serine phosphorylation of Raf-1 during mitotic arrest. 15 Our result that Lck is dispensable for Raf-1/Bcl-2 hyperphosphorylation following paclitaxel or nocodazole exposure may resolve the 'Lck paradox'. 
p38 MAP kinase is involved in TPA-mediated growth arrest but not Bcl-2 phosphorylation by microtubule active drugs
In addition to the ERK MAPK, p38 MAP kinase is activated by phorbol ester in HL-60 cells. 19 Here we demonstrate that inhibition of p38 kinase by SB202190 partially but statistically significant abolished TPA-induced growth arrest in HL-60 cells without detectable downregulation of p21 WAF1/CIP1 (Figure 6a) . Therefore, while the MAPK pathway induces p21 WAF1/CIP1 , an additional p38-dependent pathway is also involved in the growth arrest by TPA. It has been shown that the p38 kinase is activated by mammalian cells that are cAMP does not induce Bcl-2 phosphorylation but p21 WAF1/CIP1 induction. U937 cells (a) and HL60 cells (b) were treated with 10 ng/ml PMA, 100 ng/ml PTX, 10 m forskolin, 1 mm 8-brcAMP for 16 h. Immunoblot for Bcl-2 and p21 was performed as described in Methods.
arrested by nocodazole, and is required for checkpoint function in the somatic cell cycle. 21 We found that p38 kinase was not involved in Bcl-2 phosphorylation in either Jurkat cells (Figure 6b ) or HL60 cells (data not shown) following paclitaxel exposure.
cAMP-dependent kinase is involved in p21 WAF1/CIP1 induction but not in Bcl-2 phosphorylation
It has been proposed that cAMP-dependent kinase is involved in paclitaxel-induced Bcl-2 phosphorylation. 42 However, we found that neither 8-Br-cAMP nor forskolin, activators of cAMP-dependent kinases, induced Bcl-2 mobility shift in human leukemia cells (Figure 7 ). Like TPA, these agents induced p21 WAF1/CIP1 in U937 leukemia cells. Lack of detectable p21 protein in HL60 cells indicate a cell type specificity of effects which is common for differentiating agents. p21 WAF1/CIP1 induction was associated with growth arrest and was abrogated by PD98059 in U937 cells (data not shown). We conclude that p21 WAF1/CIP1 induction by phorbol ester and cAMP represents a common mechanism of growth arrest whereas Bcl-2 hyperphosphorylation is specific for microtubule-active drugs.
Discussion
Although inhibition of mitotic progression and mitotic arrest correlates with cytotoxicity of microtubule active agents, [43] [44] [45] [46] the pathways involved in cell death remain unclear. It has been shown that microtubule-active drugs, including paclitaxel and nocodazole, induce Raf-1 phosphorylation and activation. 10 induction, dephosphorylation of Rb and growth arrest. In addition, p38 kinase contributes to the growth arrest in a p21-independent manner. Since HL60, U937, K562 and Jurkat leukemia cells do not have wt p53, TPA-induction of p21 WAF1/CIP1 is p53-independent. Importantly, TPA did not induce Bcl-2 phosphorylation. In contrast to a recent report, 42 we found that cAMP and forskolin also did not induce Bcl-2 phosphorylation in leukemia cells. Like phorbol ester, c-AMP analogs induce p21 WAF1/CIP1 . These observations extend the point of view that p21 WAF1/CIP1 induction is a common mechanism of growth arrest by differentiating agents.
Microtubule-active drugs induce Bcl-2 hyperphosphorylation. It is important to emphasize that this hyperphosphorylation involves at least two serine residues 51 which dramatically changes Bcl-2 mobility. Difference between paclitaxeland RA-induced Bcl-2 phosphorylation was extensively studied by McCulloch and his group. 52 Thus, Bcl-2 phosphorylated after retinoic acid ran at the same position on SDS gels as control Bcl-2 protein. 52 Bcl-2 hyperphosphorylation precedes the PARP and Bcl-2 cleavage. It has been recently demonstrated that activation of caspase-3 may lead to cleavage of Bcl-2 at Asp34, converting Bcl-2 function from anti-apoptotic to apoptotic. 33 In the present study, we show that this occurs during drug-induced apoptosis in leukemia cells. Although the amount of cleaved Bcl-2 is relatively low and does not cause significant decrease in Bcl-2 levels, its importance could not be excluded for the following reasons. First, the cleavage occurs on the background of hyperphosphorylated Bcl-2; second, it has been shown that the cleaved product acquired Bax-like pro-apoptotic activity, 33 and finally, it may occur in a particular cellular location. In fact, Bcl-2 is located at mitochondrial, as well as nuclear and endoplasmic membranes. 53 Because of the long half-life of Bcl-2 protein, 54 phosphorylation and cleavage may be the most efficient means of Bcl-2 regulation.
In contrast to TPA, paclitaxel-mediated Raf-1 phosphorylation is PKC-independent. 27 Also, nocodazole-induced Raf-1 inactivation is independent on Ras.
14 In mitotic cells, cytoplasmic active Raf-1 kinase does not signal via the MEK/ERK pathway. 14, 15 Our data support the notion that Raf-1 during mitotic arrest does not transduce signaling via the MAPK pathways. Moreover, inhibition of MEK did not abolish the paclitaxel-induced Bcl-2 phosphorylation or cleavage nor cytotoxicity. Similarly inhibition of p38 kinase did not affect microtubule damage-induced Raf-1/Bcl-2 phosphorylation and apoptosis. The absence of MAPK activation in leukemia cells following microtubule active drugs may explain the lack of p21 WAF1/CIP1 induction. In interphase, mitogen signaling is directed from the plasma membrane to the nucleus culminating in gene expression. Therefore, receptor tyrosine kinases, Ras and other membrane-associated molecules via Raf-1 stimulate the MAPK pathways. Since the nucleus does not exist and gene expression is reduced or absent in mitosis, 55 we cannot expect that paclitaxel-activated Raf-1 transduces a signal to the nucleus or affects gene expression. Furthermore, there is no evidence that signaling by microtubule-active drugs is originated on the plasma membrane. The cytosolic location of mitotic Raf-1 supports this model. 14, 27 Consistent with this, we demonstrate that Lck tyrosine kinase which is important for signaling from membrane receptors to Raf-1 in T cells [36] [37] [38] is dispensable for paclitaxel-or nocodazole-induced Raf-1/Bcl-2 phosphorylation. Raf-1 and Bcl-2 proteins are phosphorylated exclusively on serine during mitosis, 13 making it unlikely that tyrosine kinases are involved. Ser-338, a Ras-responsive phosphorylation site, is not involved in Raf-1 activation in mitosis. 15 Taking together our results and previous reports 14, 15, 27 provide the evidence that the mechanisms responsible for activating Raf-1 during mitosis, and the subsequent downstream effects, are distinct from those involved in growth factor stimulation. Cytoplasmic location of the mitotic Raf-1 probably determines the difference.
Microtubule dynamics at mitosis depends on serine/threonine phosphorylation of microtubule-associated proteins. 56, 57 Microtubules are associated with serine/threonine kinases and phosphatases. [58] [59] [60] [61] As the plasma membrane is an important source of signals during interphase, microtubules may be a principal location of signaling following mitotic arrest. Since mitochondria, an organelle where many members of the Bcl-2 family reside, 62 has proximity to microtubules, this may direct microtubule disruption to the apoptotic machinery.
